Sticking Point: Novartis Menveo Vaccine Faces Delay Over FDA Request For Info
Although only a few months are at stake, this is the second setback this year for the product, which Novartis hopes will validate its vaccine investments.
Although only a few months are at stake, this is the second setback this year for the product, which Novartis hopes will validate its vaccine investments.